Enables sodium:potassium:chloride symporter activity. Involved in several processes, including chloride transport; metal ion transport; and positive regulation of cell volume. Acts upstream of or within gamma-aminobutyric acid signaling pathway and regulation of spontaneous synaptic transmission. Predicted to be located in several cellular components, including basolateral plasma membrane; lateral plasma membrane; and neuronal cell body. Predicted to be active in apical plasma membrane. Used to study hypertension; middle cerebral artery infarction; and visual epilepsy. Biomarker of hypertension; sensorineural hearing loss; and transient cerebral ischemia. Human ortholog(s) of this gene implicated in autosomal dominant nonsyndromic deafness 78. Orthologous to human SLC12A2 (solute carrier family 12 member 2); INTERACTS WITH (+)-pilocarpine; (R)-lipoic acid; 17beta-estradiol.
Bsc2; Nkcc1; solute carrier family 12 (sodium/potassium/chloride transporter), member 2; solute carrier family 12 (sodium/potassium/chloride transporters), member 2; solute carrier family 12, member 2
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] and [Furosemide results in decreased activity of SLC12A2 protein] promotes the reaction [Thioctic Acid results in decreased activity of Ammonia]
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of SLC12A2 mRNA
tempol inhibits the reaction [Manganese results in increased expression of SLC12A2 protein] and tempol inhibits the reaction [Manganese results in increased oxidation of SLC12A2 protein]
Uric Acid inhibits the reaction [Manganese results in increased expression of SLC12A2 protein] and Uric Acid inhibits the reaction [Manganese results in increased phosphorylation of and results in increased activity of SLC12A2 protein]
Bumetanide inhibits the reaction [SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]] and SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] more ...
[calyculin A results in increased phosphorylation of SLC12A2 protein] inhibits the reaction [Bumetanide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]] more ...
[calyculin A results in increased phosphorylation of SLC12A2 protein] inhibits the reaction [Bumetanide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium]]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA and [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
Bumetanide inhibits the reaction [SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]] and SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA and [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of SLC12A2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC12A2 mRNA
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] more ...
Bumetanide inhibits the reaction [SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]] and SLC12A2 gene mutant form promotes the reaction [Glucose results in increased secretion of INS1 protein]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA and [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA and [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA and [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA
Hydrogen Peroxide results in increased oxidation of and results in increased expression of SLC12A2 protein and Hydrogen Peroxide results in increased phosphorylation of and results in increased activity of SLC12A2 protein
[Furosemide results in decreased activity of SLC12A2 protein] affects the reaction [Thioctic Acid inhibits the reaction [Ammonia results in increased secretion of S100B protein]] and [Furosemide results in decreased activity of SLC12A2 protein] promotes the reaction [Thioctic Acid results in decreased activity of Ammonia]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine promotes the reaction [SLC12A2 protein results in increased uptake of Rubidium]] more ...
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine promotes the reaction [SLC12A2 protein results in increased uptake of Rubidium]] more ...
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC12A2 mRNA
tert-Butyl Alcohol results in increased oxidation of and results in increased expression of SLC12A2 protein and tert-Butyl Alcohol results in increased phosphorylation of and results in increased activity of SLC12A2 protein
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC12A2 mRNA
Vitamin E inhibits the reaction [Manganese results in increased expression of SLC12A2 protein] and Vitamin E inhibits the reaction [Manganese results in increased phosphorylation of and results in increased activity of SLC12A2 protein]
